ES3063733T3 - Pharmaceutical combination comprising tno155 and ribociclib - Google Patents

Pharmaceutical combination comprising tno155 and ribociclib

Info

Publication number
ES3063733T3
ES3063733T3 ES20707827T ES20707827T ES3063733T3 ES 3063733 T3 ES3063733 T3 ES 3063733T3 ES 20707827 T ES20707827 T ES 20707827T ES 20707827 T ES20707827 T ES 20707827T ES 3063733 T3 ES3063733 T3 ES 3063733T3
Authority
ES
Spain
Prior art keywords
tno155
ribociclib
pharmaceutical combination
treatment
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20707827T
Other languages
English (en)
Spanish (es)
Inventor
Ying-Nan Pan Chen
Huaixiang Hao
Chen Liu
Morvarid Mohseni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES3063733T3 publication Critical patent/ES3063733T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20707827T 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and ribociclib Active ES3063733T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962804708P 2019-02-12 2019-02-12
PCT/IB2020/051031 WO2020165734A1 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and ribociclib

Publications (1)

Publication Number Publication Date
ES3063733T3 true ES3063733T3 (en) 2026-04-20

Family

ID=69724013

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20707827T Active ES3063733T3 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and ribociclib

Country Status (14)

Country Link
US (1) US12343344B2 (cg-RX-API-DMAC7.html)
EP (1) EP3923941B1 (cg-RX-API-DMAC7.html)
JP (1) JP7493521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210126653A (cg-RX-API-DMAC7.html)
CN (1) CN113382731A (cg-RX-API-DMAC7.html)
AU (3) AU2020222296B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015632A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127286A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002099A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063733T3 (cg-RX-API-DMAC7.html)
IL (1) IL284835B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021009563A (cg-RX-API-DMAC7.html)
TW (1) TWI831916B (cg-RX-API-DMAC7.html)
WO (1) WO2020165734A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
EP3923940B1 (en) * 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
CN117642167A (zh) * 2021-05-05 2024-03-01 沪亚生物国际有限责任公司 Shp2抑制剂单一疗法及其用途
CN117177752A (zh) * 2021-05-05 2023-12-05 诺华股份有限公司 用于治疗mpnst的化合物和组合物
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
KR20240097396A (ko) 2022-12-20 2024-06-27 재단법인대구경북과학기술원 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
TWI852912B (zh) * 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
CA3123850A1 (en) 2018-12-17 2020-06-25 Lunella Biotech, Inc. Triple combination therapies for anti-aging
PE20211551A1 (es) 2018-12-17 2021-08-16 Lunella Biotech Inc Terapias de combinacion triple para fijar como objetivo mitocondrias y aniquilar celulas madre cancerosas
EP3923940B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN113382774A (zh) 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和krasg12c抑制剂的药物组合

Also Published As

Publication number Publication date
IL284835A (en) 2021-08-31
EP3923941A1 (en) 2021-12-22
JP7493521B2 (ja) 2024-05-31
CA3127286A1 (en) 2020-08-20
EP3923941B1 (en) 2025-12-03
US20220160707A1 (en) 2022-05-26
MX2021009563A (es) 2021-09-08
US12343344B2 (en) 2025-07-01
AU2020222296A1 (en) 2021-08-05
AU2020222296B2 (en) 2023-04-06
WO2020165734A1 (en) 2020-08-20
BR112021015632A2 (pt) 2021-10-05
JP2022519375A (ja) 2022-03-23
AU2023203751A1 (en) 2023-07-13
IL284835B1 (en) 2025-04-01
TWI831916B (zh) 2024-02-11
CL2021002099A1 (es) 2022-04-18
AU2025203816A1 (en) 2025-06-12
KR20210126653A (ko) 2021-10-20
IL284835B2 (en) 2025-08-01
CN113382731A (zh) 2021-09-10
TW202045171A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
CL2021002100A1 (es) Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1.
MX2021002804A (es) Terapias de combinacion.
MX2024008551A (es) Terapias de combinacion.
EP4249000A3 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
CL2020002032A1 (es) Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325).
CL2020002919A1 (es) Inhibidores de mcl-1
NI202100018A (es) Moduladores de la expresión de pnpla3
CL2023003965A1 (es) Inhibidores cdk2.
MX2020007947A (es) Inhibidores de erbb/btk.
CO2019013047A2 (es) Composiciones sólidas para administración oral
NI202000085A (es) Moduladores de la expresión de apol1
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022013081A (es) Compuestos para el tratamiento de sars.
UY39863A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe
CO2021007006A2 (es) Moduladores de la expresión de irf5
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2020009147A (es) Moduladores de la expresion de irf4.
CL2022000807A1 (es) Compuesto bicíclico y uso del mismo
CL2020002505A1 (es) Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
UY38133A (es) Nuevos inhibidores de cdk8/19
AR125874A1 (es) Terapias de combinación
CL2021002097A1 (es) Uso de triglicéridos caprílicos y cápricos para el tratamiento de una enfermedad o afección mediada por una deficiencia de filagrina o colágeno.